获得的血友病-A病例系列和审查
Liat Waldman Radinsky1, Maayan Sivan2,3, Aharon Lubetsky1,4
1National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel.
Journal of clinical medicine
|March 17, 2025
概括
获得性血友病A (AHA) 治疗包括免疫抑制疗法,埃米齐祖马布对耐药病例显示有前途. 大多数患者得到缓解,但仔细监测副作用至关重要.
科学领域:
- 血液学 血液学 血液学
- 自免疫性疾病 自免疫性疾病
- 临床研究 临床研究
背景情况:
- 获得性血友病A (AHA) 是一种罕见的,危及生命的自身免疫性疾病.
- 具有针对第八因子 (FVIII) 的自身抗体的特征,导致出血.
- 这项研究审查了一个单中心队列,以了解AHA.
研究的目的:
- 评估患者的特征,治疗方法和获得的血友病A.的结果.
- 评估不同治疗策略的有效性和安全性.
- 确定影响缓解和复发率的因素.
主要方法:
- 对22名被诊断患有AHA的成年患者 (2012-2024) 的回顾性审查.
- 数据收集包括人口统计,临床表现,实验室发现,治疗和结果.
- 统计分析比较了性别,并评估了治疗策略和缓解结果.
主要成果:
- 性别均等分布,平均年龄62岁;常见病因:异常 (45%),怀孕 (27%),恶性病 (23%).
- 最初的免疫抑制疗法 (IST) 实现了45%的缓解;埃米齐祖马布在耐药病例中显示出有前途.
- 64%的患者在3个月内缓解;14%的复发率;没有血栓事件,但发现了皮质类固醇副作用.
结论:
- IST是AHA的主要治疗方法,由于副作用,需要个性化护理.
- 埃米齐祖马布对耐火性AHA患者和脆弱人群提供了潜在的好处.
- 需要对长期结果和自发缓解进行进一步的研究,特别是在特定人群中.
相关概念视频
X-linked Traits
52.5K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
52.5K
Disorders of Hemostasis
673
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
673
Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
Introduction to Hemostasis
4.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.7K
Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K


